Journal of Leukocyte Biology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.0806542 on October 4, 2006

Published online before print October 4, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0806542v1
81/1/137    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rittirsch, D.
Right arrow Articles by Ward, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rittirsch, D.
Right arrow Articles by Ward, P. A.
(Journal of Leukocyte Biology. 2007;81:137-143.)
© 2007 by Society for Leukocyte Biology

The disconnect between animal models of sepsis and human sepsis

Daniel Rittirsch, L. Marco Hoesel and Peter A. Ward1

Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA

1Correspondence: Department of Pathology, University of Michigan Medical School, 1301 Catherine Road, Ann Arbor, MI 48109-0602, USA. E-mail: pward{at}umich.edu

Frequently used experimental models of sepsis include cecal ligation and puncture, ascending colon stent peritonitis, and the i.p. or i.v. injection of bacteria or bacterial products (such as LPS). Many of these models mimic the pathophysiology of human sepsis. However, identification of mediators in animals, the blockade of which has been protective, has not translated into clinical efficacy in septic humans. We describe the shortcomings of the animal models and reasons why effective therapy for human sepsis cannot be derived readily from promising findings in animal sepsis.

Key Words: cecal ligation and puncture • lipopolysaccharide • rodents




This article has been cited by other articles:


Home page
 FASEB J.Home page
M. A. Flierl, D. Rittirsch, B. A. Nadeau, D. E. Day, F. S. Zetoune, J. V. Sarma, M. S. Huber-Lang, and P. A. Ward
Functions of the complement components C3 and C5 during sepsis
FASEB J, October 1, 2008; 22(10): 3483 - 3490.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Chorny, P. Anderson, E. Gonzalez-Rey, and M. Delgado
Ghrelin Protects against Experimental Sepsis by Inhibiting High-Mobility Group Box 1 Release and by Killing Bacteria
J. Immunol., June 15, 2008; 180(12): 8369 - 8377.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
G. Plitas, B. M. Burt, H. M. Nguyen, Z. M. Bamboat, and R. P. DeMatteo
Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis
J. Exp. Med., June 9, 2008; 205(6): 1277 - 1283.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. A. Fowler, N. K. J. Adhikari, D. C. Scales, W. L. Lee, and G. D. Rubenfeld
Update in Critical Care 2007
Am. J. Respir. Crit. Care Med., April 15, 2008; 177(8): 808 - 819.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society for Leukocyte Biology.